AbstractPathological fear and anxiety are highly debilitating and, despite considerable advances in psychotherapy and pharmacotherapy they remain insufficiently treated in many patients with PTSD, phobias, panic and other anxiety disorders. Increasing preclinical and clinical evidence indicates that pharmacological treatments including cognitive enhancers, when given as adjuncts to psychotherapeutic approaches [cognitive behavioral therapy including extinction-based exposure therapy] enhance treatment efficacy, while using anxiolytics such as benzodiazepines as adjuncts can undermine long-term treatment success. The purpose of this review is to outline the literature showing how pharmacological interventions targeting neurotransmitter syste...
Several psychiatric conditions such as phobias, generalized anxiety, and post-traumatic stress disor...
Anxiety disorders are among the most common mental disorders. One of the most effective strategies t...
d-cycloserine (DCS), a partial NMDA-receptor agonist, seems to be a promising enhancer for exposure ...
Pathological fear and anxiety are highly debilitating and, despite considerable advances in psychoth...
AbstractPathological fear and anxiety are highly debilitating and, despite considerable advances in ...
Although exposure-based treatments and anxiolytic medications are more effective than placebo for tr...
Fear-related disorders, mainly phobias and post-traumatic stress disorder, are highly prevalent, deb...
Item does not contain fulltextAdvances in the understanding of the neurobiology of fear extinction h...
Although cognitive behavioral therapy (CBT) is a generally effective treatment for treating anxiety ...
Although exposure-based treatments and anxiolytic medications are more effective than placebo for tr...
Background: Despite its success in treating specific anxiety disorders, the effect of exposure thera...
Learning to recognize and respond to potential threats is crucial for survival. Pavlovian threat con...
Rationale : Generalized avoidance belongs to the core symptoms of a variety of anxiety disorders suc...
Current neurophysiological and psychological accounts view exposure therapy as the clinical analog o...
Several psychiatric conditions such as phobias, generalized anxiety, and post-traumatic stress disor...
Several psychiatric conditions such as phobias, generalized anxiety, and post-traumatic stress disor...
Anxiety disorders are among the most common mental disorders. One of the most effective strategies t...
d-cycloserine (DCS), a partial NMDA-receptor agonist, seems to be a promising enhancer for exposure ...
Pathological fear and anxiety are highly debilitating and, despite considerable advances in psychoth...
AbstractPathological fear and anxiety are highly debilitating and, despite considerable advances in ...
Although exposure-based treatments and anxiolytic medications are more effective than placebo for tr...
Fear-related disorders, mainly phobias and post-traumatic stress disorder, are highly prevalent, deb...
Item does not contain fulltextAdvances in the understanding of the neurobiology of fear extinction h...
Although cognitive behavioral therapy (CBT) is a generally effective treatment for treating anxiety ...
Although exposure-based treatments and anxiolytic medications are more effective than placebo for tr...
Background: Despite its success in treating specific anxiety disorders, the effect of exposure thera...
Learning to recognize and respond to potential threats is crucial for survival. Pavlovian threat con...
Rationale : Generalized avoidance belongs to the core symptoms of a variety of anxiety disorders suc...
Current neurophysiological and psychological accounts view exposure therapy as the clinical analog o...
Several psychiatric conditions such as phobias, generalized anxiety, and post-traumatic stress disor...
Several psychiatric conditions such as phobias, generalized anxiety, and post-traumatic stress disor...
Anxiety disorders are among the most common mental disorders. One of the most effective strategies t...
d-cycloserine (DCS), a partial NMDA-receptor agonist, seems to be a promising enhancer for exposure ...